In Depth 6 Aug 2024
The biggest private biotech investments in July 2024
The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.
In Depth
- Latest Posts
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
In Depth 25 Jul 2024
The future of inflammatory bowel disease treatment: what is on the horizon?
Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
In Depth 18 Jul 2024
Lenacapavir: Can Gilead’s drug end the HIV pandemic?
Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.
ADVERTISEMENT
ADVERTISEMENT
In Depth 15 Jul 2024
Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals
Discover how a new mRNA vaccine could help to tackle EEHV in elephants, which is a number one killer of Asian elephant calves.
In Depth 10 Jul 2024
Biotech’s battle against skeletal dysplasia: Ray of hope for children with rare genetic disorder
As treatments for skeletal dysplasia are intended to alleviate painful symptoms, two drugs are battling out in the clinic to prove their effectiveness.
In Depth 8 Jul 2024
Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR
Find out how the recent discovery of a molecular oddity found in bacteria has led to a new gene editing technique.
In Depth 4 Jul 2024
Parkinson’s disease: biotech’s pursuit for more therapies
Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store?
In Depth 4 Jul 2024
The biggest private biotech investments in June 2024
The companies Formation Bio, Isotopen Technologien München, and Marea Therapeutics bagged the biggest private biotech investments in June 2024.
In Depth 1 Jul 2024
Special Olympics: How is biotechnology revolutionizing sports performance worldwide?
Find out about biotechnology’s impact on sports performance and recovery, from genetic profiling, stem cells, and wearable technologies.
ADVERTISEMENT